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Schisandra chinensis is a traditional Chinese medicine that has been used for treating
insomnia and neurasthenia for centuries. Lignans, which are considered to be the bioactive
components, are apt to be extracted by supercritical carbon dioxide. This study was con-
ducted to investigate the sedative and hypnotic activities of the supercritical carbon
dioxide fluid extraction of S. chinensis (SFES) in mice and the possible mechanisms. SFES
exhibited an obvious sedative effect on shortening the locomotor activity in mice in a dose-
dependent (10e200 mg/kg) manner. SFES (50 mg/kg, 100 mg/kg, and 200 mg/kg, intra-
gstrically) showed a strong hypnotic effect in synergy with pentobarbital in mouse sleep,
and reversal of insomnia induced by caffeine, p-chlorophenylalanine and flumazenil by
decreasing sleep latency, sleep recovery, and increasing sleeping time. In addition, it
produced a synergistic effect with 5-hydroxytryptophan (2.5 mg/kg, intraperitoneally). The
behavioral pharmacological results suggest that SFES has significant sedative and hypnotic
activities, and the mechanisms might be relevant to the serotonergic and g-aminobutyric
acid (GABA)ergic system.
Copyright © 2016, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Schisandra chinensis, recorded as the ripe fruits of Schisandra
chinensis (Turcz.) Baill. in the Chinese Pharmacopoeia, has
been used as a common traditional Chinese medicine for
treating asthmatic coughing, spontaneous or night sweating,
body fluid deficiency, palpitation, and insomnia [1]. There areedicinal Materials, Jilin
Zhang).
ministration, Taiwan. Publ
.org/licenses/by-nc-nd/4.0many reports on its chemical constituents, which are mainly
lignans, polysaccharides, and organic acids [2,3]. The diben-
zocyclooctene lignans, such as schisandrol A, deoxyschizan-
drin, schisantherin A, schisandrin B, and schisandrin C, are
the major bioactive constituents for the hepatoprotective,
anticancer, antiasthmatic, antiinflammatory, sedative, hyp-
notic and anxiolytic effects, as well as the preventive effect on
Alzheimer's disease [4e16]. The ripe fruits of SchisandraAgricultural University, Changchun 130118, China.
ished by Elsevier Taiwan LLC. This is an open access article under the
/).
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Pharmacopoeia, whose composition and content of lignans
are different from S. chinensis because of their different local-
ities [17]. The sedative and hypnotic effects of the ethanol
fraction of S. sphenanthera Rehd. et Wils. has been confirmed
through the open field test and the potential pentobarbital-
induced sleep test [18]. In fact, S. chinensis was more often
used for clinical treatment of insomnia and neurasthenia
rather than S. sphenanthera in China. Therefore, this study
aimed to determine the sedative and hypnotic effects of S.
chinensis, and to explore its possible mechanisms.
Supercritical carbon dioxide extraction is widely applied in
pharmaceutical plants for its advantages in absence of sol-
vent, and high extraction efficiency [19,20]. Lignans of S. chi-
nensis have been extracted efficiently from the seeds, fruits,
caulomas, and leaves by supercritical carbon dioxide [21,22].
Schisandra lignans were extracted by supercritical carbon di-
oxide, and their hypnotic effects were superior to ethanol
extraction in subsequent experiments.2. Materials and Methods
2.1. Animals
Male Kunmingmice (22e24 g) andWister rats (200e220 g) were
purchased fromExperimental AnimalCenter of JilinUniversity,
Changchun, China, and housed in a temperature-controlled
(25 ± 1C) animal room under a 12-hour light/dark cycle with
freeaccess towater and food. The animalswere acclimatized to
the environment for 1 week, and then they were divided into
different groups randomly with 10 mice/rats each. All experi-
ments were carried out between 09:00 and 11:00 hours in a
soundproof room, and in compliance with the National In-
stitutes of Health and institutional guidelines approved by the
Animal Care Committee of Jilin Agricultural University.
2.2. Materials and extraction
S. chinensis was collected from Jilin Province, China and
identified by Professor Lianxue Zhang (College of Traditional
Chinese Medicinal Materials, Jilin Agricultural University).
Dried and pulverized fruits of S. chinensis (1 kg) were extracted
by supercritical carbon dioxide fluid, with 30 Mpa, 45C and
60 kg CO2/h for 3 hours. Finally, the yellow oil-like extract was
collected as superfluid extract of S. chinensis (SFES), and the
yield of SFES was 4.16% (w/w). Dried and pulverized fruits of S.
chinensis (100 g) were extracted with 95% ethanol by refluxing
for 2 hours, and the ethanol extract was obtained after con-
centration in vacuum as the ethanol extract of Schisandra
chinensis (SEES), and the yield of SEES was 22.1% (w/w).
2.3. Drugs and treatments
Schisandrol A, schisandrol B, schisantherin A, schisandrin A,
schisandrin B, and schisandrin C were purchased from Yua-
nye Biotech Co. Ltd. (Shanghai, China). Acetonitrile (HPLC
grade) was purchased from Honeywell Burdick & Jackson
(Ulsan, Korea). Ultrapure water was prepared in a Milli-Q
Water Purification System (Millipore, Bedford, MA, USA).Sodium pentobarbital was purchased from Dingguo Chang-
sheng Biotech Co. Ltd. (Beijing, China), with 42 mg/kg (intra-
peritoneally; i.p.) as the hypnotic dose in the experiments that
could generate 100% rate of sleep onset, and 28 mg/kg (i.p.) as
the subhypnotic dose. Caffeine (7.5 mg/kg, i.p.), 5-
hydroxytryptophan (5-HTP; 2.5 mg/kg, i.p.), flumazenil (FLU;
8 mg/kg, i.p.) and sodium carboxyl methyl cellulose (CMC-Na)
were purchased fromMelone Pharma Co. Ltd. (Dalian, China),
and diluted in 0.9% physiological saline (Dubang Pharma Co.
Ltd., Jilin, China). p-Chlorophenylalanine (PCPA, 300 mg/kg,
subcutaneously; s.c.) was suspended in 0.5% CMC-Na/
physiological saline (Melone Pharma). Diazepam (DZP)
(2 mg/kg, intragstrically; i.g.) as the positive control was pro-
vided by Yimin Pharma Co. Ltd. (Beijing, China), and SFES
(10 mg/kg, 25 mg/kg, 50 mg/kg, 100 mg/kg, and 200 mg/kg, i.g.)
were administered 30 minutes prior to the locomotor activity
test or pentobarbital administration. 5-HTP, FLU, and caffeine
were all injected 20 minutes before pentobarbital adminis-
tration. PCPA was injected 24 hours before administration of
SFES to obtain a PCPA-induced model of insomnia. All the
drug solutions were freshly prepared before use, and all the
tests were carried out between 09:00 and 11:00 hours once
daily for four consecutive days.
2.4. HPLC analysis of SFES and SEES
SFES and SEES were analyzed by HPLC [23]. Using an Agilent
1260 LC system (Agilent, Santa Clara, California, USA) equipped
with a G1314F VWD detector and an Eclipse XDB-C18 column
(4.6 mm  250 mm, 5 mm). The column temperature was 30C,
the detector wavelength was set at 220 nm, and the flow rate
was 1.0 mL/min. Ultrapure water and acetonitrile were used as
Mobile Phase A and B, respectively. The gradient elution was
programmed as follows: 0e20 minutes, 50% A; 20e30 minutes,
50e40% A; 30e40 minutes, 45e25% A; 40e50 minutes, 25% A;
50e60 minutes, 25e35% A; 60e65 minutes, 35e50% A.
The mixed reference solution was prepared with acetoni-
trile at concentrations of 120 mg/mL (schisandrol A), 45 mg/mL
(schisandrol B), 30 mg/mL (schisantherin A), 45 mg/mL (schi-
sandrin A), 120 mg/mL (schisandrin B) and 30 mg/mL (schisan-
drin C). Standard curves of the six lignans were established by
six different injection volumes (1 mL, 2 mL, 6 mL, 10 mL, 16 mL, and
20 mL) of the mixed reference solution. The solution was
filtered through a 0.45-mm membrane before liquid chro-
matogram (LC) analysis.
The sample solutions of SFES and SEES were prepared by
accuratelyweighing 0.3 g extract and transferring into a 10-mL
volumetric flask with acetonitrile. The solution was filtered
through a 0.45-mmmembrane before LC. The injection volume
of SFESwas 5 mL, while the injection volume of SEESwas 10 mL.
2.5. Locomotor activity test
The sedative effect of SFES was evaluated by detecting the
spontaneous locomotor activity in mice. Locomotor activity
and standing could be measured by the ZZ-6 locomotor ac-
tivity tester (Taimeng Software Co. Ltd., Chengdu, China),
which consisted of a microcomputer control system and six
separable reaction tanks that possessed 36 points of the
infrared array probes. Thirty minutes after oral
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ally in the locomotor activity tester. After adapting for 5 mi-
nutes, locomotor activity was recorded for 5 minutes.
2.6. Pentobarbital-induced sleep test
Animals were observed for the onset of sleep, when they were
injectedwith sodiumpentobarbital (28mg/kg or 42mg/kg, i.p.)
after administration of SFES (50 mg/kg, 100 mg/kg, or 200 mg/
kg, i.g.) or DZP (2mg/kg, i.g.) for 30minutes.When the animals
lost their righting reflex over 1 minute, they were considered
to be asleep. Sleep latency was recorded from pentobarbital
injection to sleep onset; sleep durationwas recorded from loss
of righting reflex to recovery; and sleep recovery was recorded
from recovery of righting reflex to beginning to move.
2.7. Statistical analysis
All values are presented as the mean ± standard error of the
mean. For statistical comparison, data were analyzed by one-
way analysis of variance, followed by the Stu-
denteNewmaneKeuls test. The c2 test was used to determine
the number of sleeping mice treated by subhypnotic dose of
pentobarbital (28 mg/kg). Differences with p < 0.05 were
considered as statistically significant for all the data.3. Results
3.1. HPLC analysis of SFES and SEES
All six calibration curves exhibited good linearity in the range
of 0.120e2.400 mg (schisandrol A), 0.045e0.90 mg (schisandrol
B), 0.030e0.60 mg (schisantherin A), 0.045e0.90 mg (schisandrin
A), 0.120e2.40 mg (schisandrin B), and 0.030e0.60 mg (schisan-
drin C). Linear regression equations and correlation co-
efficients (R2) were: y ¼ 5980.6x  24.747 (R2 ¼ 1) (schisandrol
A), y ¼ 11200x  20.017 (R2 ¼ 1) (schisandrol B),
y ¼ 8173.6x  8.6775 (R2 ¼ 1) (schisantherin A),
y ¼ 9487.4x þ 237.95 (R2 ¼ 0.9993) (schisandrin A),
y ¼ 6497.8x  10.308 (R2 ¼ 1) (schisandrin B), and
y ¼ 6623.5x  15.300 (R2 ¼ 1) (schisandrin C) (Table 1).
Figure 1 showed the chromatograms of the mixed stan-
dards and the SFES and SEES extracts. The content of schi-
sandrol A, schisandrol B, schisantherin A, schisandrin A,
schisandrin B, and schisandrin C in SFES and SEES was calcu-
lated from their respective standard calibration curves. TheTable 1 e Linearity calibration curves of the six lignans and th
Compounds Retention
time (min)
Standard curve R
Schisandrol A 9.661 y ¼ 5980.6x  24.747 1.00
Schisandrol B 12.802 y ¼ 11200x  20.017 1.00
Schisantherin A 29.906 y ¼ 8173.6x  8.6775 1.00
Schisandrin A 42.126 y ¼ 9487.4x þ 237.95 0.99
Schisandrin B 45.945 y ¼ 6497.8x  10.308 1.00
Schisandrin C 48.321 y ¼ 6623.5x  15.300 1.00
SEES ¼ the ethanol extract of Schisandra chinensis; SFES ¼ superfluid extotal content of the six lignans in SFES was 33.092 mg/g, while
the total content of the six lignans in SEES was 14.192 mg/g.
The lignans content was clearly higher in SFES than in SEES.
3.2. Effect of SFES on the reduction of locomotor activity
in mice
The sedative activity of SFESwas investigated by recording the
spontaneous locomotor activity of mice. Compared with the
vehicle group, SFES (10 mg/kg, 25 mg/kg, 50 mg/kg, 100 mg/kg,
and 200 mg/kg) reduced the locomotor activity of mice dose
dependently; the decreased percentage was 7.32%, 12.1%,
15.1%, 17.6%, and 22.7%, respectively. However, SFES (50 mg/
kg, 100 mg/kg, and 200 mg/kg) differed significantly compared
with the vehicle group (p < 0.05) (Table 2). The positive control
of DZP (2 mg/kg) significantly decreased the percentage of
locomotor activity in mice by 29.5% (p < 0.01). Meanwhile, the
standing counts that reflected the immobility of mice after i.g.
administration of SFES and DZP increased correspondingly.
3.3. Effect of SFES on promotion of pentobarbital-
induced sleep in mice
The hypnotic activity of SFES was evaluated by detecting the
synergistic effect with sodium pentobarbital in mice. SFES
(50mg/kg, 100mg/kg, and 200mg/kg) augmented the hypnotic
effect of pentobarbital (42mg/kg) significantlywith prolonging
sleep time (p < 0.01, Figure 2B), decreasing sleep latency
(p < 0.01, Figure 2A) and sleep recovery (p < 0.05, Figure 2C).
SFES also increased the number of mice falling asleep induced
by subhypnotic dose of pentobarbital (28 mg/kg) in a dose-
dependent manner (p < 0.05 or p < 0.01) (Table 2).
The spontaneous locomotor activity was assessed for the
sedative effect of SFES. Values are presented as
mean ± standard error of the mean (n ¼ 10 in each group),
*p < 0.05, **p < 0.01 versus vehicle group. Mice were pretreated
with CMC-Na/physiological saline, DZP and SFES 30 minutes
prior to injection of a subhypnotic dose of pentobarbital
(28 mg/kg). The number of mice falling asleep was recorded
(#p < 0.05, ##p < 0.01 vs. vehicle group, c2 test).
3.4. Effect of SFES on reversion of caffeine-induced
insomnia in mice
Caffeine-treated mice have been used as a model of insomnia
[24]. This study showed that the sleep latency and sleep re-
covery time of mice treated with caffeine (7.5 mg/kg, i.p.)eir content in SFES, SEES.
2 Liner range (mg) Content in
SFES (mg/g)
Content in
SEES (mg/g)
00 0.120e2.400 11.781 6.872
00 0.045e0.900 3.775 1.885
00 0.030e0.600 1.116 0.399
93 0.045e0.900 1.213 0.438
00 0.120e2.400 11.910 3.750
00 0.030e0.600 3.297 0.848
tract of Schisandra chinensis.
Figure 1 e HPLC of reference compounds (A), sample of SFES (B), and SEES (C). 1 ¼ Schisandrol A; 2 ¼ Schisandrol B;
3 ¼ Schisantherin A; 4 ¼ Schisandrin A; 5 ¼ Schisandrin B; 6 ¼ Schisandrin C. SEES ¼ the ethanol extract of Schisandra
chinensis; SFES ¼ superfluid extract of Schisandra chinensis.
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i.p.) significantly increased (p < 0.01, Figures 2A and 2C), and
the sleeping time decreased (p < 0.05 or p < 0.01, Figure 2B)
compared with the normal groups. SFES (50mg/kg, 100mg/kg,
and 200 mg/kg) significantly reversed insomnia in caffeine-
treated mice by decreasing sleep latency and sleep recovery
(p < 0.05 or p < 0.01, Figures 2A and 2C), and increasing the
sleeping time significantly (p < 0.01, Figure 2B). In addition, the
effects of SFES represented a dose-dependent effect.
3.5. Effect of SFES on reversion of PCPA-induced
insomnia in pentobarbital-treated mice
As described previously [25], PCPA (300 mg/kg) as an inhibitor
of tryptophan hydroxylase can induce insomnia. This study
showed that pretreatment with PCPA (300 mg/kg, s.c.)
24 hours before pentobarbital (42 mg/kg, i.p.) injection signif-
icantly increased sleep latency and sleep recovery (p < 0.01,
Figures 3A and 3C) and decreased sleep time (p < 0.01,
Figure 3B) in the vehicle group. The SFES-treated groups
significantly reversed the PCPA-induced insomnia inTable 2 e Effect of SFES on spontaneous locomotor
activity in normal mice and sleep onset of mice treated
with subhypnotic dose of pentobarbital (28 mg/kg).
Group Dosage
(mg/kg, i.g.)
Locomotion
counts in 5 min
No. falling
asleep/total
Sleep
onset (%)
Vehicle d 87.4 ± 5.5 0/10 0
DZP 2 61.6 ± 16.4** 10/10 100##
SFES 50 74.2 ± 7.6* 2/10 20#
100 72.0 ± 10.3* 6/10 60##
200 67.6 ± 16.2* 7/10 70##
DZP ¼ diazepam; i.g. ¼ intragastric; SFES ¼ superfluid extract of
Schisandra chinensis. By chi-square test (The c2 test), DZP and SFES
treated-mice vs. the vehicle group.pentobarbital-treated mice by increasing sleeping time at a
dose of 50mg/kg (p < 0.05), 100mg/kg (p < 0.01), and 200mg/kg
(p < 0.01) (Figure 3B), and reducing sleep latency at a dose of
50 mg/kg (p < 0.05), 100 mg/kg (p < 0.01), and 200 mg/kg
(p < 0.01) (Figure 3A). Meanwhile, sleep recovery was also
decreased (p < 0.05, Figure 3C).
3.6. Synergistic effect of SFES and 5-HTP in
pentobarbital-treated mice
Mice were pretreated with 5-HTP (2.5 mg/kg) 20 minutes prior
to injection of pentobarbital (42 mg/kg, i.p.) to investigate the
relationship between the hypnotic activity of SFES and the
serotonergic system (Figure 4). Neither SFES (10 mg/kg) nor 5-
HTP (2.5 mg/kg) administered individually affected sleep la-
tency or sleep duration. While the synergic effect of SFES
(10 mg/kg) and 5-HTP (2.5 mg/kg) significantly prolonged
sleeping time (p < 0.01, Figure 4B) and shortened sleep latency
(p < 0.05, Figure 4A), sleep recovery decreased but therewas no
significant difference compared with the control group
(Figure 4C).
3.7. Effect of SFES on reversion of FLU-induced insomnia
in pentobarbital-treated mice
FLU antagonizes the benzodiazepine (BZD) site of the g-
aminobutyric acid (GABA)A receptor, and inhibits sedative and
hypnotic drugs such as DZP from binding to GABAA-BZD re-
ceptors [26,27]. The synergic effect of SFES and FLU was
investigated to find the relationship of SFES with the
GABAergic system. Mice were pretreated with FLU (8 mg/kg,
i.p.) 20 minutes prior to injection of pentobarbital (42 mg/kg,
i.p.). SFES-induced decreasing of sleep latency (p < 0.01,
Figure 3A), sleep recovery (p < 0.05, Figure 3C) and increased
sleep time (p < 0.01, Figure 3B) were also found to be antago-
nized by FLU.
Figure 2 e Effect of SFES on pentobarbital-treated sleep in
normal mice 1, and the effect on caffeine-induced
insomnia mice, to which caffeine (7.5 mg/kg, i.p.) was
given 20 minutes before administration. All groups were
treated with pentobarbital (42 mg/kg, i.p.) 30 minutes
after the last administration. Sleep latency (A), sleep
duration (B), and sleep recovery (C) were assessed. All
values are presented as mean ± standard error of the
mean (n ¼ 10 in each group). *p < 0.05, **p < 0.01 versus
normal mice 1 or normal mice 2; #p < 0.05, ##p < 0.01
versus caffeine-treated group; þp < 0.05, þþp < 0.01
caffeine-treated groups versus normal mice 2.
i.p. ¼ intraperitoneally; SEES ¼ the ethanol extract of
Schisandra chinensis; SFES ¼ superfluid extract of
Schisandra chinensis.
Figure 3 e Reversion effects of SFES on PCPA-induced
insomnia in pentobarbital-treated rats, which were
pretreated with PCPA (300 mg/kg, s.c.) 24 hours prior to
injection of pentobarbital (42 mg/kg, i.p.), and the effect on
FLU-induced sleep disturbance in pentobarbital-treated
mice, which were pretreated with FLU (8 mg/kg, i.p.)
20minutesprior to injection of pentobarbital (42mg/kg, i.p.).
Sleep latency (A), sleep duration (B), and sleep recovery (C)
were assessed. All values are presented asmean± standard
error of the mean (n¼ 10 in each group) *p < 0.05, **p < 0.01
versus vehicle normal rats or normal mice; #p < 0.05,
##p < 0.01 versus vehicle model group induced by PCPA or
FLU; þp < 0.05, þþp < 0.01 model groups versus normal
groups. FLU¼flumazenil; i.p.¼ intraperitoneally; PCPA¼ p-
chlorophenylalanine; s.c.¼ subcutaneously;
SFES¼ superfluid extract of Schisandra chinensis.
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Figure 4 e Synergistic effects of SFES with 5-HTP on pentobarbital-treated sleep in mice. Mice are pretreated with 5-HTP
(2.5 mg/kg, i.p.) 20 minutes prior to injection of pentobarbital (42 mg/kg, i.p.). Sleep latency (A), sleep duration (B), and sleep
recovery (C) were assessed. All values are presented as the mean ± standard error of the mean (n ¼ 10 in each group).
*p < 0.05, **p < 0.01 versus vehicle model group treated with 5-HTP; þp < 0.05, þþp < 0.01 model groups versus normal
groups. 5-HTP ¼ 5-hydroxytryptophan; i.p. ¼ intraperitoneally; SFES ¼ superfluid extract of Schisandra chinensis.
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S. chinensis, alone or in formula, has been used for treatment of
insomnia for a long time. Lignans are the main active com-
ponents, such as schisandrol A, schisandrol B, schisandrin A,
and schisandrin B. There are many methods for extraction
and purification of lignans from S. chinensis, such as ion ex-
change resin transformation [28,29], homogeneous ionic
liquid microextraction [30], ionic liquid-based ultrasound-
assisted extraction [31], ultrasound extraction [32e34], and
supercritical fluid extraction [20]. Supercritical carbon dioxide
that is free of organic solvents was used to extract the lignans
of S. chinensis in this study. Our previous results showed that
there were >58% of lignans in the SFES by gas chromatogra-
phyemass spectrometer (GC-MS) analysis, which was more
than ethanol extraction of S. sphenanthera (33% lignans) [18].
Meanwhile, HPLC analysis of the six representative lignans
(schisandrol A, schisandrol B, schisantherin A, schisandrin A,
schisandrin B, and schisandrin C) in SFES and SEES also
showed that there were more lignans in SFES than SEES in the
same quality of extracts, although the extraction ratio of SFES
was distinctly less than SEES.
To investigate the sedative and hypnotic effects of SFES, the
locomotor activity and pentobarbital-induced sleep test in
mice were conducted, which were the two classic behavioralpharmacology methods for evaluating sedativeehypnotic ac-
tivity, because sleep as a sophisticated physiological process is
affected by a network of neuronal systems [35], which is hardly
reproduced in vitro. The decrease of spontaneous locomotion
was considered to be sedative as it reduced excitability of the
central nervous system [36]. The synergic effects of SFES and
pentobarbital on mouse sleep, in which sleep latency, dura-
tion, and recoverywere recorded,meanwhile the effect of SFES
on caffeine-induced insomnia, which was a simple and effec-
tive model of insomnia [24], were performed in this study to
detect the hypnotic activity of SFES. DZP as a typical sedative
reagent was chosen to be the positive control.
SFES significantly reduced the locomotor activity of mice
compared with the vehicle group in a dose-dependent
manner. The sleep latency was significantly shortened
(Figure 2A), the sleeping time was prolonged (Figure 2B), and
the sleep recovery, which could reflect the duration of effect
on the central nervous system after waking, was shortened at
both doses, but only the highest dose revealed a significant
difference (Figure 2C). All the effects were dose dependent. In
the caffeine-induced insomnia test (Figure 2), SFES had a
counteractive effect on the reduced sleep latency and
increased sleep duration, while sleep recovery had little
change. The above results indicate that SFES could accelerate
sleep onset, prolong sleeping time, and promote waking from
sleep in mice, and showed excellent hypnotic activity. Most
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sleep tests only selected sleep latency and duration as an
index [37,38]. Sleep recovery, which was recorded from the
recovery of righting reflex to beginning of movement, re-
flected the subsequent effect on the central nervous system.
Good potential hypnotics should not affect awakening after
sleep, and SFES showed this feature, which might have been
due to the dual regulatory effects of traditional Chinese
medicine [39].
Pharmacokinetic studies of ethanol extraction of S. chi-
nensis have revealed that the hypnotic activity might be
related to increased level of serotonin and 5-
hydroxyindoleacetic acid, and the decreased level of GABA,
norepinephrine (NE), dopamine (DA), dihydroxy-phenyl-
alanine (DOPA), and homovanillic acid (HVA) [40]. The six
lignans schisandrin, schisandrol B, schisantherin A, deoxy-
schisandrin, g-schisandrin, and gomisin Nmight be the active
components [15]. Behavioral pharmacological tests onmice or
rats about the influence of the serotonergic, noradrenergic,
dopaminergic, or GABAergic systems have never been re-
ported. The “serotonin sleep hypothesis” shows that seroto-
nin plays an important role in modulation of sleep [41,42], as
the inhibition of serotonin synthesis by PCPA induced
insomnia, and treatment with 5-HTP, a serotonin precursor,
induced drowsiness. In order to research whether the hyp-
notic effect of SFES was based on the serotonergic system, we
carried out experiments with the PCPA/5-HTP model. The re-
sults showed that SFES reversed insomnia in rats with pre-
treatment of PCPA (Figure 3), and had synergistic effects with
subhypnotic doses of 5-HTP on pentobarbital-induced sleep in
mice (Figure 4). This suggests that the serotonergic system
might be involved in the hypnotic mechanism of SFES on
pentobarbital-induced hypnosis.
GABA is an important inhibitory neurotransmitter in the
brain [43], and a lot of sedativeehypnotic drugs such as DZP,
focus on GABAA-BZD receptor binding [26]. To investigate
whether SFES had potential hypnotic effects through the
GABAergic system, the effects of coadministration of SFES and
FLU, a specific BZD antagonist, were investigated [44]. All
doses of SFES could be inhibited by FLU (Figure 3), indicating
that SFES acted at the GABAA-BZD receptors similar to DZP, so
the hypnotic effect of SFES was attributed to the modulation
of GABAA-BZD receptors through the GABAergic system.
Our previous analysis of SFES by GC-MS showed that there
were >58% of lignans in which schisandrol A and schisandrin
B comprised the majority (data not shown). The seda-
tiveehypnotic effect of schisandrin was reported to be related
to the serotonergic system but was not influenced by FLU [45].
Further studies are needed to investigate whether the modi-
fication of serotonergic system was attributed to schisandrin
alone or with other lignans, and whether the modification of
GABAergic system belonged to schisandrin B or other lignans.
The precise mechanism by which subtypes of the 5-HT re-
ceptor are related to the serotonergic system also needs
further experimentation.Conflicts of interest
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